Wockhardt LimitedNSE: WOCKPHARMA

Press Release Dec 01 2025

· Issued by Wockhardt Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Wockhardt Limited has submitted a press release regarding the acceptance of its New Drug Application for the antibiotic Zaynich by the US FDA, marking a significant milestone for the company and the Indian pharmaceutical industry. This is the first time an NDA for a New Chemical Entity from an Indian company has been accepted by the US FDA, highlighting Wockhardt's commitment to innovation and scientific excellence. The press release emphasizes Wockhardt's mission to develop advanced anti-infective therapies in response to global healthcare challenges.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Wockhardt Limited on 6ix

Earlier from Wockhardt

Later from Wockhardt

All Wockhardt news releases